Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor
Endocrinology · 06.01.2025 · 166 (2)
DOI: 10.1210/endocr/bqaf009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 17.01.2025. Verfasst von Rauf Latif und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Thyroid Research Unit, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Hauptthemen laut MEDLINE: Receptor, IGF Type 1, Receptors, Thyrotropin, Graves Ophthalmopathy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Icahn School of Medicine at Mount Sinai, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
The pathogenesis of thyroid eye disease (TED) has been suggested as due to signal enhancement in orbital fibroblasts as a result of autoantibody-induced, synergistic interaction between the TSH receptor (TSHR) and the IGF-1 receptor (IGF-1R). This interaction has been explained by a “receptor cross-talk,” mediated via β-arrestin binding. Here we have examined if this interaction can be mediated via direct receptor contact using modeling and experimental approaches. First, we docked a model of the leucine-rich domain of the TSHR ectodomain (ECD) to an available cryo-electron microscopy-based structure of the active-state IGF-1R dimer and demonstrated the stability of the complex using molecular dynamics simulations. We then extended the complex with the full-length TSHR and the transmembrane helices of the IGF1R and a 3000 ns simulation also showed stability of this complex. We then performed coimmunoprecipitation studies with anti-TSHR and anti-IGF-1R antibodies using cells expressing the IGF-1R and the full-length TSHR and also cells that expressed the IGF-1R and only the TSHR-ECD and, therefore, unable to bind β-arrestin. These studies showed a 360 kD complex protein in the immunoprecipitation, which was present in both the full-length TSHR and the TSHR-ECD-only expressing cells, evidencing a direct interaction of receptors via their ectodomains in the absence of arrestin. Colocalized staining of TSHR and IGF-1R in the TSHR-ECD cells further supported this direct interaction. These data showed that the TSHR and IGF-1R can interact directly and in the absence of β-arrestin binding. Understanding these interactions is important in the pathogenesis of TED and its therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Thyroid Research Unit, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- James J. Peters VA Medical Center, New York, NY 10468, USA.
- Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
ORCID-Profile: Rauf Latif, Mihaly Mezei, Terry F Davies
Förderung
- NCATS NIH HHS
- Icahn School of Medicine at Mount Sinai
- National Center for Advancing Translational Sciences
Zitieren
APA
Latif, R., Mezei, M., & Davies, T. F. (2025). Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor. Endocrinology, 166(2). https://doi.org/10.1210/endocr/bqaf009
Vancouver
Latif R, Mezei M, Davies TF. Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor. Endocrinology. 2025;166(2). doi:10.1210/endocr/bqaf009
BibTeX
@article{Latif2025,
author = {Latif, Rauf and Mezei, Mihaly and Davies, Terry F},
title = {Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor},
journal = {Endocrinology},
year = {2025},
volume = {166},
number = {2},
doi = {10.1210/endocr/bqaf009}
}
EUVIMED